Literature DB >> 10090468

DNA vaccines: a ray of hope.

R Tuteja1.   

Abstract

Vaccines represent the most commonly employed immunologic intervention in medicine today. DNA vaccination or genetic immunization is a rapidly developing technology that offers new approaches for the prevention of disease. This method of vaccination provides a stable and long-lived source of the protein vaccine, and it is a simple, robust, and effective means of eliciting both antibody- and cell-mediated immune responses. Furthermore, DNA vaccines have a number of potential advantages such as they can address several diseases in one vaccine, they are cheap and easy to produce and have no special cold storage requirement because they are extremely stable. It has proven to be a generally applicable technology in various preclinical animal models of infectious and noninfectious diseases, and several DNA vaccines have now entered phase I/II, human clinical trials. There are several hurdles that need to be overcome on the road to the use of DNA vaccines widely. These include the technical challenges of improving delivery and/or potency so that low doses of DNA can achieve the efficacy of conventional vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090468     DOI: 10.1080/10409239991209165

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  2 in total

1.  Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa.

Authors:  B M Price; D R Galloway; N R Baker; L B Gilleland; J Staczek; H E Gilleland
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Coexpression of 16.8 kDa antigen of Mycobacterium avium paratuberculosis and murine gamma interferon in a bicistronic vector and studies on its potential as DNA vaccine.

Authors:  Megha Kadam; Salunkhe Shardul; J L Bhagath; Vinita Tiwari; N Prasad; P P Goswami
Journal:  Vet Res Commun       Date:  2009-02-06       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.